KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

AbbVie (ABBV) Shares Issued (2016 - 2025)

AbbVie has reported Shares Issued over the past 13 years, most recently at $48.0 million for Q4 2025.

  • Quarterly Shares Issued rose 380.0% to $48.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $172.0 million through Dec 2025, down 19.63% year-over-year, with the annual reading at $172.0 million for FY2025, 19.63% down from the prior year.
  • Shares Issued was $48.0 million for Q4 2025 at AbbVie, down from $63.0 million in the prior quarter.
  • Over five years, Shares Issued peaked at $128.0 million in Q1 2022 and troughed at $5.0 million in Q2 2025.
  • The 5-year median for Shares Issued is $54.5 million (2022), against an average of $53.6 million.
  • Year-over-year, Shares Issued skyrocketed 491.67% in 2021 and then crashed 79.17% in 2024.
  • A 5-year view of Shares Issued shows it stood at $75.0 million in 2021, then decreased by 29.33% to $53.0 million in 2022, then tumbled by 41.51% to $31.0 million in 2023, then plummeted by 67.74% to $10.0 million in 2024, then surged by 380.0% to $48.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Shares Issued are $48.0 million (Q4 2025), $63.0 million (Q3 2025), and $5.0 million (Q2 2025).